Department of Endocrinology and Metabolism, Transgender Clinic, Peking University Third Hospital, Beijing, China.
Transgender Division, Beijing LGBT Center, Beijing, China.
J Sex Med. 2020 Nov;17(11):2291-2298. doi: 10.1016/j.jsxm.2020.07.081. Epub 2020 Aug 28.
Gender-affirming hormone therapy and surgery are important medically necessary approaches to transgender care. However, few related data exist in China.
To understand the desire and access of transgender cares in the Chinese transgender men and women population.
A cross-sectional self-selecting survey targeting the Chinese transgender population was conducted in 2017 using a snowball sampling method. Participants completed an online questionnaire anonymously. Gender identity was verified by specifically designed questions. Data analysis of this study was performed in 2019.
The main outcome was the status of receiving transgender medical care, including the desire vs actual state of receiving gender-affirming hormone treatment and gender-affirmation surgery, methods of accessing hormonal therapy and surgery, and risky behaviors associated with obtaining treatments.
Of the total 2060 valid questionnaires, there were 1,304 transgender individuals (626 transgender men and 678 transgender women), with a median age of 22 (interquartile range, 19-26) years. Among them, 1,036 (79.4%) expressed desires for hormonal therapy, but of 1,036, 741 (71.5%) considered it difficult to obtain medications from doctors. Of 1,036 individuals, 275 (26.5%) and 172 (16.6%) had thoughts or behaviors of self-injury, respectively, when lacking access to hormone therapy. Of 1,036 individuals, 602 (58.1%) had used hormones. Of those 602 hormone users, 407 (67.6%) had ever obtained medications from informal drug dealers, and 372 (61.8%) of them did not perform regular monitoring. 868 of 1,303 (66.6%) participants had received or wanted to undergo gender-affirming surgeries, but 710 of 868 (81.8%) considered the surgery resources not adequate or very scarce.
The transgender medical resources in China are scarce, and many transgender individuals have engaged in high-risk activities to access care.
STRENGTHS & LIMITATIONS: This is the first study to focus on the current status of gender-affirming hormone therapy and surgery in the Chinese transgender population, providing valuable and real-world data for understanding the need for transgender health care in China. But, the online questionnaire could not provide the prevalence and other epidemiologic information about transgender individuals in China, and the survey did not address specific medication regimens, dosages, sex hormone levels, and specific hormone therapy-related or surgery-related adverse events.
Significant improvement in access to gender-affirming medical and surgery care is needed in China. Liu Y, Xin Y, Qi J, et al. The Desire and Status of Gender-Affirming Hormone Therapy and Surgery in Transgender Men and Women in China: A National Population Study. J Sex Med 2020;17:2291-2298.
性别肯定激素治疗和手术是 transgender 护理中重要的医学必需方法。然而,中国相关数据很少。
了解中国 transgender 男性和女性人群中 transgender 护理的愿望和获得情况。
2017 年,采用滚雪球抽样法对中国 transgender 人群进行了一项横断面自我选择调查。参与者匿名完成在线问卷。通过专门设计的问题验证性别认同。本研究的数据分析于 2019 年进行。
在总共 2060 份有效问卷中,有 1304 名 transgender 个体(626 名 transgender 男性和 678 名 transgender 女性),中位年龄为 22 岁(四分位间距,19-26)。其中,1036 人(62.6%)表示渴望接受激素治疗,但在 1036 人中,741 人(71.5%)认为难以从医生那里获得药物。在 1036 名个体中,分别有 275 名(26.5%)和 172 名(16.6%)在缺乏激素治疗时分别有自杀想法或行为。在 1036 名个体中,有 602 名(58.1%)使用过激素。在 602 名激素使用者中,有 407 名(67.6%)曾从非正规药贩处获得过药物,其中 372 名(61.8%)未进行定期监测。在 1303 名参与者中有 868 名(66.6%)接受过或希望接受性别肯定手术,但在 868 名参与者中有 710 名(81.8%)认为手术资源不足或非常稀缺。
中国 transgender 医疗资源匮乏,许多 transgender 个体从事高风险活动以获取护理。
这是第一项专注于中国 transgender 人群中性别肯定激素治疗和手术现状的研究,为了解中国 transgender 医疗保健需求提供了有价值的真实世界数据。但是,在线问卷无法提供中国 transgender 个体的流行率和其他流行病学信息,并且调查没有涉及特定的药物方案、剂量、性激素水平以及具体的激素治疗相关或手术相关不良事件。
中国需要显著改善性别肯定医疗和手术护理的可及性。